2 studies found for:    21768458 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Recruiting Dose-confirmation Study of ASLAN001 Combined With Weekly Paclitaxel and Carboplatin in Advanced Solid Tumours, Followed by a Study in Patients With Stage I-III HER2 Positive Breast Cancer
Condition: Breast Cancer
Intervention: Drug: Paclitaxel + Carboplatin + ASLAN001
2 Active, not recruiting Doxorubicin and Cyclophosphamide Plus Paclitaxel With or Without Trastuzumab in Treating Women With Node-Positive Breast Cancer That Overexpresses HER2
Condition: Breast Cancer
Interventions: Biological: herceptin;   Drug: adriamycin;   Drug: cyclophosphamide;   Drug: taxol

Indicates status has not been verified in more than two years